Cetuximab, a chimeric anti-EGFR IgG1 monoclonal antibody, is currently an effective agent for the targeted therapy against head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) in clinical therapeutics. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.